May 25, 2022
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
Quentin Anstee joins the Surfers (including Stephen Harrison) to share lessons about the proper use of non-invasive tests in the clinical trial process and to explore implications for best practices and future research or research.
Surfing the NASH Tsunami shares Dr. Marcelo Kugelmas’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD patient screening and diagnostics along with NASH patient management. After this, he answers questions from Roger Green, who then interviews Dr. Naim Alkhouri on disease prevalence and strategies for bringing patient to be tested.
Surfing the NASH Tsunami shares Dr. Mazen Noureddin’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD pathophysiology and NASH epidemiology. After this, he answers questions from Roger Green.
Jörn Schattenberg, Louise Campbell and Roger Green wrap up the discussion of NASH drug development in 2022 by citing their reasons for optimism, ranging from what researchers have proven already about safety and efficacy to the likelihood that combination therapy will eventually become the core therapeutic strategy and the emerging importance of quality of life measures.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green all discuss the role that combination NASH drugs and greater population diversity in clinical trials will strengthen NASH drug development.
Stephen Harrison discusses the state of NASH Drug Development in 2022 with focus on the key steps on the pathway and how late-stage NASH drugs are progressing
Stephen Harrison leads a review of drug development and where we are in the NASH pipeline as Jörn Schattenberg, Louise Campbell and Roger Green lend their own perspectives and ask questions